PCSK9 and Ventricular arrhythmia: In the primary analysis of 10 trials [19–26,28], PCSK9 inhibitors did not significantly reduce the risk of ventricular arrhythmias (RR 0.81, 95% CI 0.60–1.09; P = 0.17; I2 = 0%; Fig 4).